BVS
Bioventus Inc.
$8.95
-1.00%
$768.5M
No data for this timeframe.
Vol
Market Cap$768.5M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders8 funds
Inst. Value$37.4M
Inst. Activity4 buys / 0 sells
SEC Reports8
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001665988·Prev Close $9.04
Recent Activity
Jun 3, 2026
Insider
NEELS GUIDO J sold 25,146 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Beyer Pat sold 25,146 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Ladone Mary Kay sold 25,146 shares
Director @ $0.00 ($0.00)
Jun 2, 2026
SEC
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line w
PRESS-RELEASE — Impact 6/10
Jun 2, 2026
earnings
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
<p>DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?
May 21, 2026
SEC
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class III to Class II, and
8-K — Impact 3/10
May 9, 2026
SEC
A derivative shareholder lawsuit against Bioventus and its directors/officers was dismissed without prejudice by the Del
COURT-RULING — Impact 5/10
Inst.
FMR LLC — ADD
366,686 shares ($2.7M)
Price Targets
$14.80
+60.9% upside
Strong Buy
Current $9.20
Low $14.00
Median $15.00
High $16.00
5 analysts
$14.00
$16.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 22, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 6, 2026 | Barrington Research | MAINTAIN | Outperform → Outperform |
| Mar 6, 2026 | Craig-Hallum | MAINTAIN | Buy → Buy |
| Feb 9, 2026 | Barrington Research | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.22 ▼ -8.1% | $0.20 — $0.23 | 3% YoY | 5 |
| Next Q | $0.18 ▼ -7.4% | $0.16 — $0.19 | 17% YoY | 5 |
| Current FY | $0.78 ▲ +3.5% | $0.77 — $0.78 | 14% YoY | 5 |
| Next FY | $0.91 ▲ +4.1% | $0.87 — $0.97 | 17% YoY | 5 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue of $155.4M (in line w
Jun 2, 2026
NEUTRAL
8-K
3/10
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class III to Class II, and
May 21, 2026
BULLISH
Press
8/10
Bioventus reported strong Q4 and full-year 2025 results with 10.0% organic revenue growth in Q4, GAAP profitability impr
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $22.2M | — |
| RENAISSANCE TECHNOLOGIES LLC | $4.6M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $2.8M | NEW |
| FMR LLC | $2.7M | ADD |
| MORGAN STANLEY | $2.2M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | NEELS GUIDO | A | $0.00 |
| Jun 3, 2026 | Beyer Pat | A | $0.00 |
| Jun 3, 2026 | Ladone Mary | A | $0.00 |
| Jun 3, 2026 | HAWKINS WILLIAM | A | $0.00 |
| Jun 3, 2026 | Cowdy Philip | A | $0.00 |
8 institutional holders with $37.4M total value (5,024,945 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,984,927 | $22.2M | 59.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 615,100 | $4.6M | 12.2% | ADD +42.9% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 375,173 | $2.8M | 7.5% | NEW |
| 4 | FMR LLC | 366,686 | $2.7M | 7.3% | ADD +25.3% |
| 5 | MORGAN STANLEY | 302,258 | $2.2M | 6.0% | TRIM -62.7% |
| 6 | TWO SIGMA INVESTMENTS, LP | 268,833 | $2.0M | 5.3% | ADD +31.1% |
| 7 | BANK OF AMERICA CORP /DE/ | 61,334 | $456.3K | 1.2% | ADD +89.4% |
| 8 | WELLS FARGO & COMPANY/MN | 50,634 | $376.7K | 1.0% | ADD +74.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 292,534 | 366,686 | +25.3% | $2.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 205,026 | 268,833 | +31.1% | $2.0M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 32,390 | 61,334 | +89.4% | $456.3K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 29,070 | 50,634 | +74.2% | $376.7K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 652,911 | 243,749 | -62.7% | $1.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 205,026 | — | $1.4M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 553,500 | 790,818 | +42.9% | $5.2M | 2025-Q2 |
| MORGAN STANLEY | ADD | 493,118 | 652,911 | +32.4% | $4.3M | 2025-Q2 |
| FMR LLC | TRIM | 998,349 | 301,596 | -69.8% | $2.0M | 2025-Q2 |
| UBS Group AG | ADD | 46,172 | 87,613 | +89.8% | $580.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 125,972 | 41,190 | -67.3% | $272.7K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 35,572 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 388,700 | 553,500 | +42.4% | $5.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 51,930 | 86,317 | +66.2% | $789.8K | 2025-Q1 |
| MORGAN STANLEY | TRIM | 1,007,676 | 642,602 | -36.2% | $6.7M | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 325,470 | 51,930 | -84.0% | $545.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 17,035 | 22,494 | +32.0% | $236.2K | 2024-Q4 |
| MORGAN STANLEY | ADD | 523,441 | 1,007,676 | +92.5% | $12.0M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 390,162 | — | $4.7M | 2024-Q3 |
14 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | NEELS GUIDO J | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | Beyer Pat | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | Ladone Mary Kay | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | HAWKINS WILLIAM A | Director | A | 30,994 | $0.00 | $0.00 |
| Jun 3, 2026 | Cowdy Philip G. | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | STALNECKER SUSAN M | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | McMurry-Heath Michelle | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | SUTTER MARTIN P | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | NOHRA GUY P | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 3, 2026 | Bartholdson John A. | Director | A | 25,146 | $0.00 | $0.00 |
| Jun 2, 2026 | Beyer Pat | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Beyer Pat | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Ladone Mary Kay | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Ladone Mary Kay | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | HAWKINS WILLIAM A | Director | M | 39,789 | $0.00 | $0.00 |
| Jun 2, 2026 | HAWKINS WILLIAM A | Director | M | 39,789 | $0.00 | $0.00 |
| Jun 2, 2026 | STALNECKER SUSAN M | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Cowdy Philip G. | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Cowdy Philip G. | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | NEELS GUIDO J | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | NEELS GUIDO J | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | McMurry-Heath Michelle | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | McMurry-Heath Michelle | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | NOHRA GUY P | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | STALNECKER SUSAN M | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | NOHRA GUY P | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | SUTTER MARTIN P | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | SUTTER MARTIN P | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Bartholdson John A. | Director | M | 32,282 | $0.00 | $0.00 |
| Jun 2, 2026 | Bartholdson John A. | Director | M | 32,282 | $0.00 | $0.00 |
| Apr 10, 2026 | D'Adamio Anthony | SVP & General Counsel | M | 9,925 | $0.00 | $0.00 |
| Apr 10, 2026 | D'Adamio Anthony | SVP & General Counsel | F | 4,312 | $9.06 | $39.1K |
| Apr 10, 2026 | D'Adamio Anthony | SVP & General Counsel | M | 9,925 | $0.00 | $0.00 |
| Apr 10, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | M | 4,300 | $0.00 | $0.00 |
| Apr 10, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | F | 1,868 | $9.06 | $16.9K |
| Apr 10, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | M | 4,300 | $0.00 | $0.00 |
| Apr 10, 2026 | Singleton Mark Leonard | SVP & CFO | M | 13,000 | $0.00 | $0.00 |
| Apr 10, 2026 | Singleton Mark Leonard | SVP & CFO | F | 5,648 | $9.06 | $51.2K |
| Apr 10, 2026 | Singleton Mark Leonard | SVP & CFO | M | 13,000 | $0.00 | $0.00 |
| Mar 20, 2026 | Singleton Mark Leonard | SVP & CFO | M | 18,625 | $0.00 | $0.00 |
| Mar 20, 2026 | Singleton Mark Leonard | SVP & CFO | F | 8,091 | $8.64 | $69.9K |
| Mar 20, 2026 | Singleton Mark Leonard | SVP & CFO | M | 18,625 | $0.00 | $0.00 |
| Mar 13, 2026 | Claypoole Robert E | President and CEO | M | 33,500 | $0.00 | $0.00 |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | F | 3,861 | $8.62 | $33.3K |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | A | 83,000 | $0.00 | $0.00 |
| Mar 13, 2026 | D'Adamio Anthony | SVP & General Counsel | A | 92,000 | $0.00 | $0.00 |
| Mar 13, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | A | 24,000 | $0.00 | $0.00 |
| Mar 13, 2026 | CHURCH KATRINA J | SVP & Chief Compliance Officer | M | 3,455 | $0.00 | $0.00 |
| Mar 13, 2026 | Singleton Mark Leonard | SVP & CFO | A | 116,000 | $0.00 | $0.00 |
| Mar 13, 2026 | Singleton Mark Leonard | SVP & CFO | A | 104,000 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 4 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 5.1/10.
BEARISH
PRESS-RELEASE
6/10
Bioventus (BVS) reported Q1 2026 EPS of $0.15, a 30.6% miss versus the $0.22 consensus, on revenue o
Jun 2, 2026
NEUTRAL
8-K
3/10
Bioventus disclosed that the FDA reclassified its Exogen Ultrasound Bone Healing System from Class I
May 21, 2026
BULLISH
COURT-RULING
5/10
A derivative shareholder lawsuit against Bioventus and its directors/officers was dismissed without
May 9, 2026
BULLISH
8-K
7/10
Bioventus reported Q1 2026 revenue of $132.1M (+6.6% YoY) and GAAP EPS of $0.04, improving from a -$
May 6, 2026
BULLISH
PRESS-RELEASE
8/10
Bioventus reported Q1 2026 revenue of $132.1M (+7% YoY) and GAAP EPS of $0.04, swinging from a -$0.0
May 6, 2026
NEUTRAL
PRESS-RELEASE
2/10
Bioventus announces Q1 2026 earnings release date for May 6, 2026, before market open. No financial
Apr 28, 2026
NEUTRAL
DEFA14A
2/10
Bioventus Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting
Apr 22, 2026
BULLISH
8-K
8/10
Bioventus reported strong Q4 2025 results with $157.9M revenue (2.8% YoY growth, 10% organic growth)
Mar 5, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.80 mean target
+60.9% upside
Strong Buy (3.00)
$14.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $9.20 |
| Target Low | $14.00 |
| Target Mean | $14.80 |
| Target Median | $15.00 |
| Target High | $16.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.22 | $0.20 | $0.23 | 2.9% | -8.1% | 0↑ 3↓ | $0.2B | 5.3% | 5 |
| Next Q 2026-09-30 |
$0.18 | $0.16 | $0.19 | 17.3% | -7.4% | 0↑ 1↓ | $0.1B | 7.3% | 5 |
| Current FY 2026-12-31 |
$0.78 | $0.77 | $0.78 | 14.1% | +3.5% | 3↑ 0↓ | $0.6B | 6.6% | 5 |
| Next FY 2027-12-31 |
$0.91 | $0.87 | $0.97 | 16.8% | +4.1% | 5↑ 0↓ | $0.6B | 6.6% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.216 | |
| 7d ago | $0.217 | -0.002 |
| 30d ago | $0.235 | -0.019 |
| 60d ago | $0.225 | -0.009 |
| 90d ago | $0.237 | -0.021 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 22, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Barrington Research | MAINTAIN | Outperform | Outperform |
| Mar 6, 2026 | Craig-Hallum | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Barrington Research | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 1 | 5 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 1 | 5 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
earnings
Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference
<p>DURHAM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=PPAKoAaQQUXQ4omwkdMUUxPpd-cDI0k_dPWypqL4rim3_
May 8, 2026
Enforcement
Jung Jae Hyung, Derivatively on Behalf of Bioventus Inc. v. Kenneth M. Reali, Mark L. Singleton, Gregory O. Anglum, Susan M. Stalnecker, William A. Hawkins, III, John A. Bartholdson, Patrick J. Beyer, Phillip G. Cowdy, Mary Kay Ladone, Michelle McMurray-Heath, Guido J. Neels, Guy P. Nohra, David J. Parker, Martin P. Sutter, and Stavros G. Vizirgiankis
Court ruling from District Court, D. Delaware. Docket: 1:25-cv-00806
May 6, 2026
earnings
Bioventus Reports First Quarter Financial Results
<p>DURHAM, N.C., May 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for ac
May 6, 2026
earnings_calendar
BVS Q1 2026 Earnings Scheduled — 2026-05-06
May 4, 2026
earnings_calendar
BVS Q1 2026 Earnings Scheduled — 2026-05-04
Apr 28, 2026
earnings
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
<p>DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a7o-JozEPP_clolmsGGN9mXLP7rdp0pfzm_oxgrDaMBB
Mar 5, 2026
earnings
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
<p><br>DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations
Mar 5, 2026
earnings_calendar
BVS Q4 2025 Earnings After Market Close — 2026-03-05